Reaction

Mastication Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,010 reports · 88 co-occurring drugs

As of the last recalculation, Mastication Disorder appears in 3,010 FAERS reports alongside 88 co-occurring drug terms. The strongest observed disproportionality signal is RAVULIZUMAB (PRR 43.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ravulizumab	82	43.1	43.4
Thiamine Hydrochloride	28	15.7	15.7
Botulinum Toxin Type A	26	14.6	14.6
Chlorhexidine Gluconate	18	13.7	13.7
Tolterodine Tartrate	15	11.6	11.6
Zoledronic Acid	65	11.4	11.4
Eculizumab	86	11.2	11.3
Onabotulinumtoxina	119	11.1	11.1
Melphalan	35	10.8	10.8
Melphalan Hydrochloride	37	10.3	10.3
Cinacalcet Hydrochloride	65	9.8	9.8
Risedronate Sodium	41	9.2	9.2
Mometasone	24	9.1	9.1
Alendronate Sodium	126	9.0	9.0
Cimetidine	12	8.6	8.7
Clindamycin Phosphate	38	8.0	8.0
Goserelin	15	7.8	7.8
Clindamycin	31	7.6	7.6
Primidone	11	7.5	7.5
Bicalutamide	16	7.3	7.3
Quinine	9	7.3	7.3
Thalidomide	38	7.2	7.2
Meperidine Hydrochloride	9	6.8	6.8
Docusate Sodium - Sennosides	31	6.7	6.7
Sirolimus	13	6.7	6.7
Azithromycin	38	6.6	6.6
Amoxicillin And Clavulanate Potassium	25	6.4	6.4
Azithromycin Monohydrate	38	6.4	6.4
Mometasone Furoate	37	6.2	6.2
Exemestane	19	6.2	6.2
Cefazolin	8	6.1	6.1
Amlodipine Besylate And Benazepril Hydrochloride	8	6.0	6.0
Thyroid, Porcine	9	5.9	5.9
Ampicillin	7	5.9	5.9
Ampicillin Sodium	7	5.9	5.9
Denosumab	163	5.8	5.8
Cefazolin Sodium	10	5.8	5.8
Erythropoietin	17	5.7	5.8
Azithromycin Dihydrate	48	5.7	5.7
Fulvestrant	27	5.7	5.7
Drs. Clotrimazole	9	5.4	5.4
Family Wellness Clotrimazole	9	5.4	5.4
Clotrimazole Topical	9	5.4	5.4
Letrozole	44	5.0	5.0
Sunitinib Malate	28	5.0	5.0
Olanzapine Pamoate	28	4.8	4.8
Terazosin Hydrochloride	6	4.7	4.7
Metoclopramide Hydrochloride	51	4.6	4.6
Nicotine Polacrilex Mini	10	4.6	4.6
Nicotine Polarilex	10	4.6	4.6
Lovastatin	17	4.6	4.6
Extended Phenytoin Sodium	11	4.6	4.6
Metoclopramide	35	4.4	4.5
Carbidopa And Levodopa	30	4.4	4.4
Fexofenadine	10	4.2	4.2
Guaifenesin	18	4.1	4.1
Rivastigmine	11	4.0	4.1
Naproxen Sodium, Dextromethorphan Hydrobromide, Guaifenesin	12	4.0	4.0
Naproxen Sodium, Pseudoephedrine Hydrochloride	12	4.0	4.0
Buprenorphine Hydrochloride, Naloxone Hydrochloride	14	4.0	4.0
Ziprasidone Mesylate	8	3.9	3.9
Valbenazine	14	3.9	3.9
Rasagiline Mesylate	6	3.7	3.7
Nicotine Polacrilex	20	3.6	3.6
Teduglutide	7	3.6	3.6
Ziprasidone	9	3.5	3.5
Loratadine And Pseudoephedrine Sulfate	4	3.5	3.5
Clobazam	12	3.4	3.4
Tenofovir Disoproxil Fumarate Tablets	4	3.2	3.2
Asenapine Maleate	4	3.2	3.2
Fesoterodine Fumarate	5	3.2	3.2
Risperidone	56	2.9	2.9
Darbepoetin Alfa	21	2.7	2.7
Paliperidone	9	2.7	2.7
Conjugated Estrogens And Medroxyprogesterone Acetate	9	2.6	2.6
Paliperidone Palmitate	12	2.6	2.6
Axitinib	7	2.5	2.5
Travoprost	3	2.4	2.4
Cabozantinib	16	2.3	2.3
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	3	2.3	2.3
Acalabrutinib	4	2.3	2.3
Ruxolitinib	23	2.2	2.2
Osimertinib	10	2.2	2.2
Cannabidiol	7	2.1	2.1
Vigabatrin	4	1.9	1.9
Pseudoephedrine Hcl	3	1.9	1.9
Pimavanserin Tartrate	15	1.9	1.9
Abaloparatide	6	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.